Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
We have shown that following priming with replicating adenovirus type 5 host range mutant (Ad5hr)-human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) recombinants, boosting with gp140 envelope protein enhances acute-phase protection against intravenous simian/human immunodeficiency virus (SHIV)(89.6P) challenge compared to results with priming and no boosting or boosting with an HIV polypeptide representing the CD4 binding site of gp120. We retrospectively analyzed antibodies in sera and rectal secretions from these same macaques, investigating the hypothesis that vaccine-elicited nonneutralizing antibodies contributed to the better protection. Compared to other immunized groups or controls, the gp140-boosted group exhibited significantly greater antibody activities mediating antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated viral inhibition (ADCVI) in sera and transcytosis inhibition in rectal secretions. ADCC and ADCVI activities were directly correlated with antibody avidity, suggesting the importance of antibody maturation for functionality. Both ADCVI and percent ADCC killing prechallenge were significantly correlated with reduced acute viremia. The latter, as well as postchallenge ADCVI and ADCC, was also significantly correlated with reduced chronic viremia. We have previously demonstrated induction by the prime/boost regimen of mucosal antibodies that inhibit transcytosis of SIV across an intact epithelial cell layer. Here, antibody in rectal secretions was significantly correlated with transcytosis inhibition. Importantly, the transcytosis specific activity (percent inhibition/total secretory IgA and IgG) was strongly correlated with reduced chronic viremia, suggesting that mucosal antibody may help control cell-to-cell viral spread during the course of infection. Overall, the replicating Ad5hr-HIV/SIV priming/gp140 protein boosting approach elicited strong systemic and mucosal antibodies with multiple functional activities associated with control of both acute and chronic viremia.
Xiao
Peng
P
NIH, NCI, 41 Medlars Drive, Building 41, Room D804, Bethesda, MD 20892-5065, USA.
Zhao
Jun
J
Patterson
L Jean
LJ
Brocca-Cofano
Egidio
E
Venzon
David
D
Kozlowski
Pamela A
PA
Hidajat
Rachmat
R
Demberg
Thorsten
T
Robert-Guroff
Marjorie
M
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D015686:Gene Products, env / Q000276:immunology*; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D008253:Macaca mulatta; D008297:Male; D012007:Rectum / Q000276:immunology / Q000821:virology; D018449:SAIDS Vaccines / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014766:Viremia / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D053586:Virus Internalization
D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D018449:SAIDS Vaccines
J Virol. 2004 Mar;78(6):3140-4
14990733
Nat Med. 2009 Jan;15(1):34-41
19079256
J Immunol. 2006 Sep 15;177(6):4028-36
16951366
Science. 2008 May 9;320(5877):760-4
18467582
Nat Med. 1997 Jun;3(6):651-8
9176492
Cell. 1991 Dec 20;67(6):1121-9
1760840
Vaccine. 2005 Mar 31;23(19):2522-9
15752839
J Infect Dis. 2004 Dec 1;190(11):1970-8
15529262
J Virol. 1999 May;73(5):4009-18
10196297
Virology. 2008 Dec 20;382(2):217-25
18947849
Virology. 2006 Sep 15;353(1):83-98
16814356
Curr Opin HIV AIDS. 2009 Sep;4(5):388-93
20048702
Nat Med. 2000 Jun;6(6):607-8
10835650
J Biol Chem. 1996 Jul 26;271(30):17990-5
8663408
Nat Med. 2002 Feb;8(2):150-6
11821899
J Immunol Methods. 2006 Jan 20;308(1-2):53-67
16343526
Nature. 2008 Oct 2;455(7213):613-9
18833271
Nat Med. 2000 Feb;6(2):200-6
10655110
Nat Med. 2009 Mar;15(3):293-9
19219024
J Immunol. 2004 Mar 15;172(6):3745-57
15004179
J Virol. 2009 Jul;83(13):6508-21
19403685
J Virol. 1997 Nov;71(11):8531-41
9343211
Nat Med. 2003 Jul;9(7):847-52
12835704
Science. 2001 Apr 6;292(5514):69-74
11393868
Nat Rev Immunol. 2005 Oct;5(10):783-92
16200081
Nat Med. 2002 Feb;8(2):114-6
11821891
J Immunol. 2005 Feb 15;174(4):2185-9
15699150
AIDS Rev. 2003 Jul-Sep;5(3):178-85
14598567
J Exp Med. 2009 May 11;206(5):1117-34
19414559
Curr HIV Res. 2008 Nov;6(6):515-9
18991616
J Immunol. 2007 May 15;178(10):6596-603
17475891
Mucosal Immunol. 2009 Sep;2(5):412-26
19587640
Virology. 2008 May 10;374(2):322-37
18252262
J Virol. 2004 Mar;78(5):2212-21
14963117
N Engl J Med. 2009 Dec 3;361(23):2209-20
19843557
J Immunol. 2000 Nov 1;165(9):5170-6
11046049
Nature. 2007 Sep 6;449(7158):101-4
17805298
Vaccine. 2004 Dec 16;23(5):615-22
15542181
AIDS Res Hum Retroviruses. 1989 Dec;5(6):557-63
2692657
AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1197-205
12487826
J Immunol. 1996 Sep 1;157(5):2168-73
8757343
J Virol. 2009 May;83(9):4102-11
19224993
AIDS Res Hum Retroviruses. 1990 Mar;6(3):341-56
1971182
J Virol. 2006 Sep;80(18):9217-25
16940533
Science. 2000 Oct 20;290(5491):486-92
11039923
Nature. 1984 Nov 15-21;312(5991):271-5
6504141
J Virol. 2001 Aug;75(15):6953-61
11435575
J Virol. 2007 Apr;81(7):3414-27
17229693
Science. 1989 Jun 9;244(4909):1152-7
2658060
J Immunol. 2001 May 15;166(10):6257-65
11342649
Immunity. 1998 Aug;9(2):277-87
9729048
Nat Med. 1997 Jan;3(1):42-7
8986739
Mucosal Immunol. 2009 Nov;2(6):536-50
19741603
Nat Rev Immunol. 2006 Dec;6(12):930-9
17124514
Nat Med. 2000 Feb;6(2):207-10
10655111
Vaccine. 2003 May 16;21(17-18):2190-6
12706710
J Virol. 2004 Jul;78(14):7490-7
15220422
J Clin Immunol. 2001 May;21(3):227-33
11403230
Expert Opin Biol Ther. 2008 Sep;8(9):1347-63
18694354
J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7
16940858
Nat Med. 1999 Feb;5(2):204-10
9930869
J Immunol. 2009 Mar 15;182(6):3718-27
19265150
J Virol. 2009 Jan;83(2):791-801
18971271